Navigation Links
Rib-X Pharmaceuticals Antibiotic Drug Discovery Platform Discovers Novel Compounds with Activity Against Key Multiple Drug Resistant Gram-negative Bacteria
Date:8/31/2009

that are active against Gram-negative bacteria. This program exploits the peptidyl transferase region of the 50S subunit, which is the catalytic region of the ribosome and the binding site of many chemically distinct classes of antibiotics, including oxazolidinones (e.g., linezolid), lincosamides (e.g., clindamycin), phenyl propanoids (e.g., chloramphenicol), pleuromutilins (e.g., retapamulin), macrolides/ketolides (e.g., azithromycin) and sparsomycin. Rib-X has created five completely novel series of compounds targeting two novel sites that show good antibacterial activity against a number of clinically important multi drug resistant Gram-negative pathogens.

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotics that can be used for the treatment of either community- or hospital-acquired infections. In addition to Rx-04, Rib-X has successfully completed Phase 2 trials with delafloxacin (RX-3341), a broad spectrum fluoroquinolone with potent activity against quinolone resistant Gram-positive bacteria including MRSA. Radezolid (RX-1741), an oxazolidinone that was discovered at Rib-X, as an oral/IV agent for treatment of ser
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
2. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference
3. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
4. Rib-X Pharmaceuticals to Present at the 2008 ICAAC/IDSA Joint Meeting
5. Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing
6. Rib-X Pharmaceuticals Announces Presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
7. Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors
8. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
(Date:1/14/2014)... 13, 2014 Bob Hainsey, a semiconductor ... 20 years in the industry, has joined SPIE, ... will serve as the society’s Science and Technology Strategist. ... SPIE as our Technology Strategist, further strengthening the technical ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors contributed unknowingly to ... time period, doctors did not know that they needed to ... of vulnerable patients. In the same way, medical interns and ... transmitting herpes viruses to their patients. The CBCD explains. , ...
(Date:1/14/2014)... BioMedomics, Inc. , a Point of Care ... novel disease specific POC tests, announced today that it has ... of $690,000. The investment is from private investors and is ... of private investors has significant successful experience in early investments ...
Breaking Biology Technology:Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3BioMedomics, Inc. Closes $690K Round of Financing 2
... Investment Conference on... -- HARBIN, China, Sept. 7 /PRNewswire-Asia-FirstCall/ -- ... ... --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
... Calif., Sept. 7 / PRNewswire/ -- Transdel ... announced that Transdel management will present a company overview at ... York City on Monday, September 13, 2010 at 4:05 p.m. ... webcast via the Internet by visiting the Investor Relations section ...
... Exclusive Partnership Agreements for Immunotherapy Tablets in Japan -- ANTONY, France, September 6, 2010 ... ... --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
Cached Biology Technology:Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 2Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 3Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 4Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 5Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 6Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 7Transdel Pharmaceuticals to Present at Rodman & Renshaw 12th Annual Healthcare Conference 2Transdel Pharmaceuticals to Present at Rodman & Renshaw 12th Annual Healthcare Conference 3Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 2Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 3Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 4Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 5Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 6Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 7Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 8Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 9
(Date:4/17/2014)... cells in bone marrow need to produce hydrogen sulfide ... according to a new study from the Center for ... Dentistry of USC. , Professor Songtao Shi, principal investigator ... produced by the cells governs the flow of calcium ... signals that results in osteogenesis, or the creation of ...
(Date:4/17/2014)... of forests in the Amazon help create tinderbox ... rapid and widespread forest loss during drought years, ... show that forests in the Amazon could reach ... forest fires lead to large-scale loss of trees, ... professor of geography, Penn State. , "We documented ...
(Date:4/17/2014)... -- Indiana University researchers have detected new early-warning signs ... This discovery could have far-reaching implications for the diagnosis ... of over 25 million Americans. , "We had not ... at such early stages," said Ann Elsner, professor and ... lead author of the study. "We set out to ...
Breaking Biology News(10 mins):Drought and fire in the Amazon lead to sharp increases in forest tree mortality 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 3New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3
... To most people in the southwestern U.S., the April 4 ... But on a group of inch-long fish that exist nowhere ... the ground in Nevada,s Mojave Desert, it unleashed a veritable ... the event on cameras installed above and below the water,s ...
... (EPA) has awarded nearly $2.5 million to 11 ... environmental areas: monitoring and control of air emissions, ... monitoring, water infrastructure, homeland security, nanotechnology and innovation ... of concept" awards from EPA, and will use ...
... JOLLA, Calif., May 11, 2010 -- Investigators from around ... on Friday, May 7, to share their knowledge of ... non-coding nucleic acids turn off proteins and have been ... numerous other conditions. "The discovery that small ...
Cached Biology News:'Tsunami' video sheds light on struggling pupfish 2'Tsunami' video sheds light on struggling pupfish 3'Tsunami' video sheds light on struggling pupfish 4'Tsunami' video sheds light on struggling pupfish 5EPA awards small businesses to develop new environmental technologies 2Researchers share insights into RNA 2
Endothelin-converting enzyme 1 (EC 3.4.24.71) (ECE-1). [Source:Uniprot/SWISSPROT;Acc:P42892] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Red Standard is sodium salt of resorufin....
Oligodendrocyte Marker O1 MAb (Clone O1)...
ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2)...
Biology Products: